Biomarkers, Surrogate Endpoints and Clinical Outcomes: Understanding the Difference
The short answer
A biomarker is a measurable characteristic that indicates a biological process or response. A clinical outcome describes how a person feels, functions or survives. A surrogate endpoint is a biomarker or intermediate measure used in place of a clinical outcome because it is expected to predict benefit or harm.
The terms are connected, but they are not interchangeable. A change in a biomarker can be scientifically meaningful without proving that people experience a meaningful clinical benefit.
What is a biomarker?
The FDA–NIH BEST framework defines a biomarker as a measured characteristic indicating normal biological processes, pathogenic processes or responses to an exposure or intervention. Biomarkers may be molecular, histologic, radiographic or physiologic.
Examples can include a laboratory value, receptor-occupancy measure, imaging result or gene-expression pattern. A biomarker is not itself a measure of how someone feels, functions or survives.
What is an endpoint?
An endpoint is a precisely defined variable selected to answer a research question. A study should specify what is measured, how it is measured, when it is assessed and how the result will be analyzed.
Endpoints may be mechanistic, pharmacokinetic, biomarker-based or clinical. The endpoint must be interpreted in the context of the study design rather than by its name alone.
Clinical outcomes
Clinical outcomes directly reflect how a person feels, functions or survives. Depending on the study, they may include symptoms reported by participants, the ability to perform an activity, a clinically meaningful event or survival.
A statistically significant laboratory change is not automatically a clinical outcome. Researchers must determine whether the observed difference is large enough, reliable enough and relevant to the people being studied.
Surrogate endpoints
A surrogate endpoint substitutes for a direct clinical outcome because it is expected to predict benefit or harm. Some surrogates are well validated for a defined context. Others are considered reasonably likely to predict benefit but still require confirmatory evidence.
Validation is context-specific. A marker that predicts an outcome in one disease, population or intervention class may not do so in another. Biological plausibility alone is not sufficient.
Why surrogate reasoning can fail
An intervention may improve a marker without changing the clinical outcome of interest. It may also affect other pathways that offset the expected benefit or introduce harm. Associations observed in untreated populations do not necessarily show that changing the marker through an intervention will change the outcome.
This is why regulatory and scientific frameworks distinguish biomarkers, candidate surrogates, validated surrogates and direct clinical outcomes.
Reading peptide-related evidence carefully
Peptide studies may report receptor activation, hormone concentrations, inflammatory markers, imaging changes, body composition or other measurable endpoints. Each can contribute useful evidence, but none should be described more broadly than the study supports.
Ask whether the article reports a mechanistic marker, a surrogate or a direct outcome; whether the endpoint was prespecified; how many comparisons were made; whether the change was clinically meaningful; and whether the result was replicated.
Key points
- Biomarkers measure biological characteristics or responses.
- Clinical outcomes directly reflect feeling, function or survival.
- Surrogate endpoints are expected to predict clinical outcomes, but their validity is context-specific.
- Statistical significance does not automatically mean clinical importance.
- A biomarker result should not be rewritten as a proven health outcome.
What this article does not establish
This article does not interpret an individual’s laboratory results, provide medical advice or establish the safety or effectiveness of an AURAPEP product.
References
- FDA–NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. https://www.ncbi.nlm.nih.gov/books/NBK338448/
- U.S. Food and Drug Administration. About Biomarkers and Qualification. https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification
- U.S. Food and Drug Administration. FDA Facts: Biomarkers and Surrogate Endpoints. https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints
- U.S. Food and Drug Administration. BEST Resource Taxonomy. https://www.fda.gov/drugs/development-resources/best-resource-taxonomy